Alumis Inc. (ALMS) 股票分析

公司概述

Alumis Inc. operates as a clinical stage biopharmaceutical enterprise dedicated to the research, development, and commercialization of therapeutic agents specifically designed to address autoimmune disorders. The company functions within the broader healthcare sector and the specialized biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory hurdles prior to market entry. As of the latest available data, Alumis Inc. maintains a market capitalization of $2.92B and employs a workforce of 221 individuals to support its scientific and operational objectives. The annual revenue generated over the trailing twelve months stands at $24.05M, indicating that while the company possesses a substantial market valuation relative to its current sales, its financial scale is currently driven by future pipeline potential rather than extensive commercial revenue streams typical of mature pharmaceutical firms.

财务健康

The financial profile of Alumis Inc. reveals a revenue of $24.05M for the trailing twelve months, contrasted sharply by a net income of -$243,324,992 and an EBITDA of -$438,408,000. The substantial negative gap between the modest revenue figure and the deep losses in net income highlights a cost structure heavily weighted toward research and development expenses and operational overheads that have not yet been offset by commercial sales. Free cash flow for the period was recorded at -$202,334,000, which signifies that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital raising or asset monetization. Margin analysis shows a gross margin of 100.0%, suggesting that the cost of goods sold is negligible or fully covered by revenue at the unit level, though this is typical for early-stage biotechs where manufacturing costs are low relative to R&D. However, the operating margin stands at -5067.1% and the profit margin is 0.0%, reflecting the extreme expense intensity inherent in clinical-stage development before profitability is achieved. On the balance sheet, the company holds $308.50M in cash against $36.91M in debt, resulting in a debt-to-equity ratio of 12.25. Despite the high leverage ratio, the liquidity position appears robust given the significant cash reserves relative to outstanding obligations. The current ratio is 4.34, indicating that the company possesses more than four times the current assets necessary to cover its short-term liabilities, pointing to strong short-term liquidity. Return on Equity is -86.7% and Return on Assets is -73.4%, metrics that reveal the company is currently destroying value per unit of capital employed as it invests heavily in its pipeline to achieve future product launches.

估值评估

Valuation metrics for Alumis Inc. present a mixed picture of market expectations and financial realities, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -7.09. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings potential that is currently obscured by present losses, suggesting expectations of significant future profitability once clinical trials succeed. The price-to-book ratio is 7.97, indicating that the market assigns a substantial premium to the company's intangible assets, such as its drug pipeline and intellectual property, over the tangible book value of its balance sheet. Alternative valuation measures include a price-to-sales ratio of 121.33 and an EV/EBITDA of -6.04, which suggest the stock is priced based on revenue multiples common in the biotech sector rather than earnings or cash flow multiples. Regarding trading range, the 52-week high is $30.60 and the 52-week low is $2.76, placing the current share price in a volatile trajectory relative to this historical range. The beta value is N/A, meaning that standard volatility metrics relative to the broader market index are not available for this specific security.

Growth & Income

Growth metrics for Alumis Inc. show revenue growth (YoY) and earnings growth (YoY) both listed as N/A, reflecting the challenges in calculating year-over-year percentage changes when prior year figures are negligible or when the company is in a pre-revenue or pre-consistent-earnings phase. Because the company has not generated consistent positive earnings, the concept of earnings growing faster than revenue is not currently applicable, and the focus remains entirely on pipeline advancement rather than top-line expansion rates. Alumis Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all available cash to reinvest into its research and development activities rather than distributing income to shareholders. Consequently, the overall growth and income profile of Alumis Inc. is defined by capital allocation toward clinical progress and regulatory approval rather than dividend income or consistent historical growth rates.